Coldstream Laboratories Announces New VP of Manufacturing

Coldstream Laboratories Announces New VP of Manufacturing
 
LEXINGTON, KY, Nov 21, 2011 (MARKETWIRE via COMTEX) -- Coldstream Laboratories, Inc., a provider of drug product research and manufacturing services, has named Dr. Vickie Hall as Vice President of Manufacturing.

In her new position, Hall will assume responsibility of Coldstream's manufacturing, facilities, and warehouse operations. As a member of the company's executive leadership team, she will help drive the company's strategic growth.

Hall brings to Coldstream over 20 years of experience in managing research, product development, manufacturing and operations for vaccines and pharmaceuticals. Most recently, she served as Executive Director of Manufacturing Science and Technology at Ben Venue Labortories, Inc., a subsidiary of the Boehringer Ingelheim Corporation.

"We are pleased to announce the addition of Vickie Hall to Coldstream's executive leadership team," said Coldstream President and CEO Larry Kranking. "Vickie brings a wealth of knowledge and experience to our corporation that will prove invaluable as we continue to grow and look towards expansion in the coming years."

Coldstream Laboratories, Inc. is a specialty manufacturer of sterile injectable drugs and operates Kentucky's only sterile pharmaceutical manufacturing facility. For more information, visit www.coldstreamlabs.com or email [email protected]

 

       
        Contact:
        Kathy Bennett
        Coldstream Laboratories
        Email Contact
        
        
       

 

SOURCE: Coldstream Laboratories

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.